Updates

** Shares of Hims & Hers Health HIMS.N fall 28.5% to $16.45; the lowest since October 2024

** Stock is on track for its steepest single‑day drop since June 2025

** Novo Nordisk NOVOb.CO shares up 5.2%, on track for best day since December; Eli Lilly's LLY.N shares rise 4.5%

** Novo says it has filed a lawsuit against Hims & Hers for infringing on the Danish group's patents

** "Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages," Novo says

** Hims says the lawsuit is a "blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care"

** "Once again, Big Pharma is weaponizing the U.S. judicial system to limit consumer choice," Hims says in a response on the X platform

** HIMS said on Saturday it would stop offering its compounded $49 GLP-1 weight-loss pill after the U.S. FDA threatened action against the co, citing potential violation of federal law

** HIMS declined about 47% YTD, underperforming a 1.3% rise in the S&P 500 .SPX

(Reporting by Rashika Singh and Siddhi Mahatole in Bengaluru)

((Rashika.Singh@thomsonreuters.com;))